PCA
CRL icon

Personal Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Personal Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$35M Sell
160,483
-16,743
-9% -$3.66M 0.17% 115
2022
Q3 		$34.9M Buy
177,226
+12,654
+8% +$2.73M 0.19% 111
2022
Q2 		$35.2M Buy
164,572
+12,446
+8% +$3.04M 0.18% 113
2022
Q1 		$43.2M Buy
152,126
+10,756
+8% +$3.32M 0.2% 114
2021
Q4 		$53.4M Sell
141,370
-612
-0.4% -$238K 0.25% 94
2021
Q3 		$58.6M Sell
141,982
-73,597
-34% -$30.6M 0.29% 79
2021
Q2 		$79.7M Sell
215,579
-239
-0.1% -$79.8K 0.41% 44
2021
Q1 		$62.6M Buy
215,818
+82
+0% +$22.8K 0.36% 59
2020
Q4 		$53.9M Sell
215,736
-2,980
-1% -$710K 0.34% 66
2020
Q3 		$49.5M Sell
218,716
-4,632
-2% -$961K 0.37% 60
2020
Q2 		$38.9M Sell
223,348
-1,991
-0.9% -$318K 0.32% 77
2020
Q1 		$28.5M Buy
225,339
+1,034
+0.5% +$155K 0.28% 84
2019
Q4 		$34.3M Buy
224,305
+94,680
+73% +$13.1M 0.29% 86
2019
Q3 		$17.2M Buy
129,625
+4,350
+3% +$583K 0.16% 112
2019
Q2 		$17.8M Sell
125,275
-13,687
-10% -$1.86M 0.18% 110
2019
Q1 		$20.2M Buy
138,962
+3,637
+3% +$478K 0.23% 99
2018
Q4 		$15.3M Buy
135,325
+808
+0.6% +$101K 0.21% 105
2018
Q3 		$18.1M Buy
134,517
+2,238
+2% +$276K 0.23% 102
2018
Q2 		$14.8M Buy
132,279
+2,325
+2% +$251K 0.21% 103
2018
Q1 		$13.9M Buy
129,954
+4,648
+4% +$501K 0.22% 102
2017
Q4 		$13.7M Buy
125,306
+4,699
+4% +$511K 0.23% 97
2017
Q3 		$13M Sell
120,607
-7,063
-6% -$726K 0.25% 92
2017
Q2 		$12.9M Sell
127,670
-9,821
-7% -$904K 0.28% 85
2017
Q1 		$12.3M Sell
137,491
-27,765
-17% -$2.36M 0.31% 86
2016
Q4 		$12.6M Buy
165,256
+14,305
+9% +$1.09M 0.37% 82
2016
Q3 		$12.5M Buy
150,951
+16,389
+12% +$1.37M 0.42% 78
2016
Q2 		$11.1M Buy
134,562
+16,118
+14% +$1.33M 0.43% 78
2016
Q1 		$8.99M Buy
118,444
+12,732
+12% +$942K 0.41% 80
2015
Q4 		$8.5M Buy
105,712
+14,812
+16% +$1.07M 0.47% 73
2015
Q3 		$5.77M Buy
90,900
+11,387
+14% +$818K 0.38% 79
2015
Q2 		$5.65M Buy
+79,513
New +$5.88M 0.39% 78

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Personal Capital Advisors's CRL Position: Q4 2022 in Review

Personal Capital Advisors reduced its Charles River Laboratories (CRL) stake by 9.4% in Q4 2022, selling an estimated $3.66M and leaving 160,483 shares worth $35M. The position accounts for 0.17% of the portfolio, ranked #115.

Personal Capital Advisors first reported a position in CRL in Q2 2015 and has held it in 31 quarters since. The position peaked at $79.7M in Q2 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Personal Capital Advisors held 160,483 shares of Charles River Laboratories worth $35M as of Q4 2022.
  • Personal Capital Advisors sold 16,743 Charles River Laboratories shares in Q4 2022, an estimated $3.66M.
  • Charles River Laboratories made up 0.17% of Personal Capital Advisors's portfolio in Q4 2022, its #115 holding.
  • Personal Capital Advisors first reported a position in Charles River Laboratories in Q2 2015 and has held it in 31 quarters since.
  • Personal Capital Advisors's Charles River Laboratories position peaked at $79.7M in Q2 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.